Imaging features of toxicities associated with immune checkpoint inhibitors
Gosangi, Babina McIntosh, Lacey J Keraliya, Abhishek Irugu, David Victor Kumar Baheti, Akshay Khandelwal, Ashish Thomas, Richard Braschi-Amirfarzan, Marta
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
ARDS, acute respiratory distress syndrome
CTCAE, Common Terminology Criteria for Adverse Events
CTLA-4 inhibitor, Cytotoxic T-lymphocyte antigen- 4 inhibitor
Colitis
FDA, Food and Drug Administration
Hepatitis
ICI, Immune check point inhibitor
Immune check point inhibitors toxicity
LGE, late Gadolinium enhancement
NSCLC, non-small cell lung cancer
NSIP, non-specific interstitial pneumonia
OP, organizing pneumonia
PD-1 inhibitor, programmed cell death-1 inhibitor
PD-L1 inhibitor, programmed cell death ligand-1 inhibitor
PFS, progression free survival
Pancreatitis
Pneumonitis
RRP, radiation recall pneumonitis
irAE, immune-related adverse event
Subject Area
Collections
Files
Embargo Expiration Date
Link to Full Text
Abstract
The past decade has witnessed a change in landscape of cancer management with the advent of precision oncology. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and have played an important role in improving patient survival. While the patients are living longer, treatment with ICIs are sometimes associated with adverse effects, some of which could be fatal. Radiologists can play a crucial role by early identification of some of these adverse effects during restaging scans. Our paper focuses on the imaging features of commonly occurring ICI toxicities based on organ system.
Source
Gosangi B, McIntosh L, Keraliya A, Irugu DVK, Baheti A, Khandelwal A, Thomas R, Braschi-Amirfarzan M. Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open. 2022 Aug 8;9:100434. doi: 10.1016/j.ejro.2022.100434. PMID: 35967881; PMCID: PMC9372737.